SI-BONE, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SI-BONE, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $67.30M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $55.38M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $47.98M | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $200.93M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $167.18M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $138.89M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $106.41M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $90.15M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $73.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $67.30M | Mar 10, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.88M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $132.12M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $109.42M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $90.70M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $79.72M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $64.49M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $60.51M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $50.55M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $42.87M | Mar 14, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.90M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($30.91M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($43.34M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($61.26M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | ($56.57M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($43.70M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($38.40M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($17.45M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($23.04M) | Mar 14, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.33M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($35.25M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($46.93M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($59.61M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | ($51.67M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($38.57M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($36.00M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($11.97M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($17.35M) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.45M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $16.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $15.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $13.63M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $12.44M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $9.46M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $7.28M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $5.38M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.51M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($675.0K) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($12.43M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($18.71M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($41.66M) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | ($39.53M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($30.66M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($31.63M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($14.52M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($17.53M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $10.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $9.51M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $6.39M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $2.56M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.45M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $942.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $478.0K | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $230.44M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $230.43M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $157.55M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $190.51M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $223.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $117.01M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $138.52M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $35.83M | Mar 14, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.02M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $63.47M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $61.05M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $59.25M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $56.09M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $53.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $54.00M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $48.33M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $46.66M | Mar 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.53M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $166.96M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $169.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $98.30M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $134.42M | Feb 25, 2025 |
| FY2022 | Dec 31, 2020 | $169.36M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $63.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $90.19M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | ($129.38M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($108.73M) | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($450.26M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($431.35M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($400.44M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($357.11M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($295.85M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($239.28M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($195.58M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($157.18M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($139.72M) | Mar 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $34.95M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $33.27M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $20.72M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $63.42M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $53.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $10.44M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $25.12M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $22.41M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $27.90M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.57M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $35.45M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $36.07M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $35.17M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $34.97M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $39.46M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $39.22M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $38.96M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $38.70M | Mar 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | (1) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | (1) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.65M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 42.09M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 40.69M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 34.73M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 33.67M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 32.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 25.16M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 24.45M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 3.60M | Mar 14, 2019 |